Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults

Eczema, also called atopic dermatitis, is a common skin condition that makes your skin dry, itchy, and red. For many people with eczema, especially milder forms, doctors often recommend a combination of steroid creams and a special type of moisturiser called an emollient. Emollients are very important because they help to repair your skin's barrier, keeping moisture in and irritants out.

However, using emollients every day can sometimes feel like a lot of work. This can make it hard for people to stick to their treatment plan, leading to their eczema flaring up or feeling like their current cream isn't working as well. Another challenge is that, unlike some steroid creams, emollients are often not covered by national health insurance in France, meaning patients have to pay for them themselves. This can add stress and cost for families dealing with a long-term skin condition.

Scientists at Laboratoires Gilbert have been working on a new emollient. They've discovered an active ingredient from seawater, called Active Oligo Skin, which they've included in their new cream, Relipid+. Early tests have suggested this ingredient could help soothe inflamed and irritated skin. The main goal of this study is to compare how well this new Relipid+ cream works against a very popular and often recommended emollient called Lipikar Baume AP+M (from La Roche-Posay). The researchers believe Relipid+ will be at least as effective, and they're also interested in seeing if it helps the balance of healthy bacteria on the skin, which is thought to be important for managing eczema.